Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Adenocarcinoma: early-phase trial registry
31 of 63 indexed Pancreatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 31 currently recruiting · #222 of 28,707 conditions by registered trial count
Pancreatic Adenocarcinoma: 63 US clinical trials tracked, 31 recruiting.
Pancreatic Adenocarcinoma is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 31 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition pancreatic-adenocarcinoma
OPEN 31 | RECR 49% | LATE 1 | EARLY 46 | RANK #222 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Anxiety Disorders (49% recruiting · 85 trials)
Pancreatic Adenocarcinoma lists 31 open slots (49% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Adenocarcinoma is recruiting above its size-band peers.
31 of 63 indexed trials (49.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Adenocarcinoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 4 of 63 trials (6.3%). 53 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreatic Adenocarcinoma enrolment sits around 66 participants.
Median target enrolment is 66 among the 63 trials that report a genuine target (sentinel values excluded). 37 of those (58.7%) plan for fewer than 100 participants.
-
Pancreatic Adenocarcinoma research is mostly interventional.
53 interventional and 10 observational studies make up this index (84.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 1 of 2
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Mayo Clinic
NCT00830557
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Guardant Health
NCT05059444
Pancreatic Cancer Detection Consortium
City of Hope Medical Center
NCT06388967
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02757859
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
M.D. Anderson Cancer Center
NCT01365169
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Global Development
NCT05365581
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT05245500
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
NCT05985655
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma
NCT05933265
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT06789172
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
UNC Lineberger Comprehensive Cancer Center
NCT06483555
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
Cedars-Sinai Medical Center
NCT06988150
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
NCT05988918
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
University of Chicago
NCT04361708
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT05877599
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT04605913
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Ashish Manne
NCT05624918
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Alpha Tau Medical
NCT06698458
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
George Poultsides
NCT03384238
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Baylor Research Institute
NCT04926467
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
NCT06412510
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University
NCT05482516
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Diakonos Oncology Corporation
NCT04157127
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Anwaar Saeed
NCT06896188
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
NCT03080974
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
Beth Israel Deaconess Medical Center
NCT05973331
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics
NCT03678883
Pancreatic Cancer Biomarker Study
Van Andel Research Institute
NCT04143152
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT05585320
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics
NCT05651022
Pancreatic Cancer Early Detection Program
White Plains Hospital
NCT02206360
Predicting Effective Therapy in Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT03033927
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT03816358
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Colin D. Weekes, M.D., PhD
NCT05077800
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT02495896
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
NCT03073785
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
University of Florida
NCT03483038
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
NCT04539808
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Andrew Hendifar, MD
NCT04098237
Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
M.D. Anderson Cancer Center
NCT04837118
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
HonorHealth Research Institute
NCT03138720
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
NCT02336087
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06466187
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT03245541
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 15 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Adenocarcinoma page
63 registered trials, 31 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 31 Pancreatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Adenocarcinoma condition card totals 63 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.